vs
ANAPTYSBIO, INC（ANAB）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
ANAPTYSBIO, INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.6倍（$108.2M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 45.8%，领先338.2%），ANAPTYSBIO, INC同比增速更快（151.1% vs 21.2%），过去两年ANAPTYSBIO, INC的营收复合增速更高（288.3% vs 53.7%）
AnaptysBio是一家处于临床阶段的生物技术企业，专注于开发适用于炎症疾病、肿瘤免疫及罕见病领域的抗体类免疫疗法，主要面向美国市场，推进创新候选药物管线研发以满足未被满足的临床需求。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
ANAB vs RIGL — 直观对比
营收规模更大
ANAB
是对方的1.6倍
$69.8M
营收增速更快
ANAB
高出129.9%
21.2%
净利率更高
RIGL
高出338.2%
45.8%
两年增速更快
ANAB
近两年复合增速
53.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $108.2M | $69.8M |
| 净利润 | $49.6M | $268.1M |
| 毛利率 | — | 91.5% |
| 营业利润率 | 61.8% | 33.2% |
| 净利率 | 45.8% | 384.0% |
| 营收同比 | 151.1% | 21.2% |
| 净利润同比 | 327.8% | 1769.2% |
| 每股收益（稀释后） | $1.64 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANABRIGL
| Q4 25 | $108.2M | $69.8M | ||
| Q3 25 | $76.3M | $69.5M | ||
| Q2 25 | $22.3M | $101.7M | ||
| Q1 25 | $27.8M | $53.3M | ||
| Q4 24 | $43.1M | $57.6M | ||
| Q3 24 | $30.0M | $55.3M | ||
| Q2 24 | $11.0M | $36.8M | ||
| Q1 24 | $7.2M | $29.5M |
净利润ANABRIGL
| Q4 25 | $49.6M | $268.1M | ||
| Q3 25 | $15.1M | $27.9M | ||
| Q2 25 | $-38.6M | $59.6M | ||
| Q1 25 | $-39.3M | $11.4M | ||
| Q4 24 | $-21.8M | $14.3M | ||
| Q3 24 | $-32.9M | $12.4M | ||
| Q2 24 | $-46.7M | $-1.0M | ||
| Q1 24 | $-43.9M | $-8.2M |
毛利率ANABRIGL
| Q4 25 | — | 91.5% | ||
| Q3 25 | — | 93.2% | ||
| Q2 25 | — | 95.6% | ||
| Q1 25 | — | 91.7% | ||
| Q4 24 | — | 89.9% | ||
| Q3 24 | — | 85.5% | ||
| Q2 24 | — | 92.4% | ||
| Q1 24 | — | 93.1% |
营业利润率ANABRIGL
| Q4 25 | 61.8% | 33.2% | ||
| Q3 25 | 45.5% | 40.9% | ||
| Q2 25 | -117.5% | 60.1% | ||
| Q1 25 | -99.2% | 23.9% | ||
| Q4 24 | -22.4% | 28.9% | ||
| Q3 24 | -75.8% | 25.4% | ||
| Q2 24 | -367.5% | 1.2% | ||
| Q1 24 | -587.8% | -23.6% |
净利率ANABRIGL
| Q4 25 | 45.8% | 384.0% | ||
| Q3 25 | 19.8% | 40.2% | ||
| Q2 25 | -173.5% | 58.6% | ||
| Q1 25 | -141.6% | 21.5% | ||
| Q4 24 | -50.5% | 24.9% | ||
| Q3 24 | -109.4% | 22.5% | ||
| Q2 24 | -425.3% | -2.8% | ||
| Q1 24 | -612.0% | -27.9% |
每股收益（稀释后）ANABRIGL
| Q4 25 | $1.64 | $14.11 | ||
| Q3 25 | $0.52 | $1.46 | ||
| Q2 25 | $-1.34 | $3.28 | ||
| Q1 25 | $-1.28 | $0.63 | ||
| Q4 24 | $-0.63 | $0.82 | ||
| Q3 24 | $-1.14 | $0.70 | ||
| Q2 24 | $-1.71 | $-0.06 | ||
| Q1 24 | $-1.64 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $238.2M | $155.0M |
| 总债务越低越好 | — | $52.5M |
| 股东权益账面价值 | $37.2M | $391.5M |
| 总资产 | $364.4M | $513.6M |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ANABRIGL
| Q4 25 | $238.2M | $155.0M | ||
| Q3 25 | $109.8M | $137.1M | ||
| Q2 25 | $44.3M | $108.4M | ||
| Q1 25 | $98.6M | $77.1M | ||
| Q4 24 | $123.1M | $77.3M | ||
| Q3 24 | $191.6M | $61.1M | ||
| Q2 24 | $71.8M | $49.1M | ||
| Q1 24 | $53.7M | $49.5M |
总债务ANABRIGL
| Q4 25 | — | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益ANABRIGL
| Q4 25 | $37.2M | $391.5M | ||
| Q3 25 | $-29.4M | $117.6M | ||
| Q2 25 | $-44.7M | $81.9M | ||
| Q1 25 | $34.0M | $18.6M | ||
| Q4 24 | $70.9M | $3.3M | ||
| Q3 24 | $84.4M | $-14.6M | ||
| Q2 24 | $9.9M | $-29.9M | ||
| Q1 24 | $47.8M | $-31.7M |
总资产ANABRIGL
| Q4 25 | $364.4M | $513.6M | ||
| Q3 25 | $353.1M | $242.5M | ||
| Q2 25 | $335.3M | $206.7M | ||
| Q1 25 | $422.1M | $176.0M | ||
| Q4 24 | $483.8M | $164.0M | ||
| Q3 24 | $493.4M | $139.4M | ||
| Q2 24 | $427.4M | $128.4M | ||
| Q1 24 | $405.8M | $126.5M |
负债/权益比ANABRIGL
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $98.0M | — |
| 自由现金流率自由现金流/营收 | 90.5% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 1.98× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $19.6M | — |
8季度趋势，按日历期对齐
经营现金流ANABRIGL
| Q4 25 | $98.0M | $22.0M | ||
| Q3 25 | $-27.4M | $24.0M | ||
| Q2 25 | $-40.2M | $30.5M | ||
| Q1 25 | $-10.7M | $-893.0K | ||
| Q4 24 | $-66.7M | $14.5M | ||
| Q3 24 | $-10.1M | $21.7M | ||
| Q2 24 | $-21.3M | $302.0K | ||
| Q1 24 | $-37.3M | $-5.0M |
自由现金流ANABRIGL
| Q4 25 | $98.0M | — | ||
| Q3 25 | $-27.4M | — | ||
| Q2 25 | $-40.3M | — | ||
| Q1 25 | $-10.7M | — | ||
| Q4 24 | $-66.9M | — | ||
| Q3 24 | $-10.1M | — | ||
| Q2 24 | $-21.4M | — | ||
| Q1 24 | $-37.3M | — |
自由现金流率ANABRIGL
| Q4 25 | 90.5% | — | ||
| Q3 25 | -35.9% | — | ||
| Q2 25 | -180.9% | — | ||
| Q1 25 | -38.7% | — | ||
| Q4 24 | -155.3% | — | ||
| Q3 24 | -33.7% | — | ||
| Q2 24 | -194.6% | — | ||
| Q1 24 | -519.3% | — |
资本支出强度ANABRIGL
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.4% | — |
现金转化率ANABRIGL
| Q4 25 | 1.98× | 0.08× | ||
| Q3 25 | -1.81× | 0.86× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | — | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
